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Ectromelia virus (ECTV) is an orthopoxvirus (OPV) that causes mousepox, the murine equivalent of human smallpox.
C57BL/6 (B6) mice are naturally resistant to mousepox due to the concerted action of innate and adaptive immune
responses. Previous studies have shown that natural killer (NK) cells are a component of innate immunity that is
essential for the B6 mice resistance to mousepox. However, the mechanism of NK cell–mediated resistance to OPV
disease remains undefined. Here we show that B6 mice resistance to mousepox requires the direct cytolytic function of
NK cells, as well as their ability to boost the T cell response. Furthermore, we show that the activating receptor NKG2D
is required for optimal NK cell–mediated resistance to disease and lethality. Together, our results have important
implication towards the understanding of natural resistance to pathogenic viral infections.
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Introduction
Ectromelia virus (ECTV), the causative agent of mousepox,
is an orthopoxvirus (OPV) with host specificity for the mouse.
It is genetically very similar to vaccinia virus (VACV), the
human pathogen variola virus (the agent of smallpox), and
monkeypox virus [1], which sporadically infects people in
Africa and produced a recent outbreak in the midwestern
United States [2,3]. Like smallpox, mousepox is a severe
disease with high mortality and infectivity. Thus, mousepox
constitutes an excellent model to study smallpox and
exanthematous diseases in general [4].
Although all mouse strains can be infected with ECTV, the
outcome of the infection following footpad inoculation varies.
Some sensitive strains, such as DBA/2, A/J, and BALB/c,
develop mousepox and suffer high mortality during the first
2 wk post-infection, whereas other strains, such as C57BL/6
(B6), clear the infection without visible symptoms of systemic
disease [5]. The resistance of B6 mice to mousepox is not due
to an inherent decreased ability of the virus to replicate in this
strain, but is a result of the combined action of the innate and
adaptive immune systems [6–8].
Natural killer (NK) cells are innate effector cells serving as a
first line of defense against certain viral infections and
tumors [9,10]. For example, NK cell–deficient individuals
become sick or succumb to normally non-life-threatening
infections with the herpes virus human cytomegalovirus
(HCMV) or varicella zoster [11–13]. In addition, C57BL/6
mice, which are normally resistant to mouse cytomegalovirus
(MCMV), become susceptible when NK cells are depleted [14].
Similarly, NK cells have been shown to be crucial for the
resistance of B6 mice to mousepox [15–17].
The activation of NK cells is regulated by a balance of
signals transduced by activating and inhibitory receptors
[18,19]. It is thought that continuous signaling through
inhibitory receptors maintain NK cells in a resting state,
and the loss of inhibitory signals (i.e., due to downregulation
of MHC class I on target cells) or the expression of ligands for
activating receptors on target cells results in NK cell
activation [19]. Previous studies have shown that Rmp1, a
dominant gene important for the ability of B6 mice to resist
mousepox, maps to the ‘‘NK complex,’’ a region of
chromosome 6 that encodes a large number of NK cell–
activating and inhibitory receptors [16,18]. Well-defined
activating receptors encoded by polymorphic genes within
the NK complex in B6 mice include NKR-P1C (NK1.1, the
prototypic marker defining NK cells in B6 mice), the Ly49
family members Ly49H and Ly49D, NKG2D, CD94-NKG2C,
and CD94-NKG2E. Cmv1, a gene responsible for the resist-
ance of B6 mice to MCMV infection and also mapped to the
NK complex, has been shown to be the activating receptor
Ly49H that binds to the MCMV-encoded MHC-like protein
m157 expressed on the surface of infected cells [20–23]. On
the other hand, the positive identification of any activating
NK cell receptor involved in resistance to mousepox is still
lacking, even though it has been speculated that Rmp1 might
be the prototypic activating receptor NK1.1 [24].
In this study, we show that NK cells directly contribute to
antiviral defenses by curbing virus dissemination to central
organs and also indirectly by augmenting the antiviral T cell
response. We also demonstrate that the activating receptor
NKG2D is involved in the NK cell–mediated resistance to
mousepox, whereas NK1.1 is not.
Results
Resistance to Mousepox Requires NK Cells, but Only
during the First 4 d Post-Infection
B6 mice are normally resistant to mousepox ([5] and Table
1). To determine whether and when NK cells are required for
resistance to mousepox, we depleted NK cells in B6 mice at
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different times following ECTV infection with either anti-
asialo GM1 antiserum or anti-NK1.1 mAb PK136. Anti-asialo
GM1 antiserum depletes NK cells and some activated T cells
but not NKT cells, whereas PK136 depletes NK cells and NKT
cells but not T cells. Thus, the use of both Abs allowed us to
better distinguish the role of NK cells from that of other
lymphocyte populations. As shown in Table 1, depletion of
NK cells with either Ab on or before day 4 post-infection (PI)
with 3,000 pfu ECTV resulted in very high mortality, while
mock-depleted mice (normal rabbit sera for anti-asialo GM1
and mouse IgG2a for PK136) were still resistant (data not
shown). On the other hand, resistance to mousepox was
maintained when mice were depleted of NK cells on day 6 PI,
indicating an important role for the physical presence of NK
cells at the early, but not later, stages of infection. In
additional experiments, we found that five out of five and two
out of five PK136-depleted B6 mice succumbed when infected
with 100 and 1 pfu ECTV, respectively. Identical results were
obtained for BALB/c mice infected with the same virus stock.
This shows that the susceptibility of B6 mice depleted of NK
cells on the day of infection is similar to that of genetically
susceptible BALB/c mice. In agreement with the increased
mortality, NK cell depletion resulted in severe necrosis and
splenic lymphopenia as compared to non-depleted (intact) B6
mice (Figure 1A). Furthermore, 7 d PI, NK cell–depleted mice
had more than 103-fold higher viral titers in both the spleen
and liver than intact mice (Figure 1B), indicating a more
severe systemic infection in the absence of NK cells. Thus, NK
cells are required in the early phase of infection to control
viral loads in central organs and to resist lethal mousepox.
Early Recruitment of NK Cells to the Draining Lymph
Nodes
We next evaluated the NK cell response at different times
PI by flow cytometry. NK cell production of IFN-c and
granzyme B (GzB) in the draining lymph nodes (D-LN) was
already induced 24 h PI, reaching the peak at 48 h PI when
;20% of the NK cells produced IFN-c and 43% produced
GzB (Figure 1C and 1D), a time when T cell responses were
not yet detected [25]. This was accompanied by a 2- to 4-fold
increase in the proportion of NK cells in the D-LN (Figure
1D). NK cell responses in non-draining LN and spleen,
however, did not peak until day 5 PI (Figure 1C). In addition,
histopathological analysis of the infected footpads on day 2 PI
did not show leukocyte infiltration or other signs of
inflammation in either intact or NK cell–depleted B6 mice
(data not shown). Thus, at very early stages of infection the
NK cell response is restricted to the D-LN.
To distinguish whether the increase in NK cell number in
D-LN resulted from recruitment and/or proliferation, we
inoculated mice at different stages of infection with BrdU IP
and sacrificed the mice 3 h later to determine BrdU
incorporation by flow cytometric analysis. Very few NK cells
incorporated BrdU in the D-LN during the first 3 d PI,
suggesting increased migration to the D-LN at early times PI.
In fact, on day 3 and 5 PI, the BrdU incorporation in NK cells
in spleen and liver was higher than in the D-LN (Figure 1E).
Thus, the increase of NK cells in the D-LN on day 2 PI is
mostly due to recruitment rather than proliferation.
A recent report by Hayakawa and Smyth revealed that
peripheral NK1.1þ NK cells can be divided into three subsets
according to their expression of CD11b and CD27, which they
designated R1 (CD27þ, CD11b), R2 (CD27þ, CD11bþ), and R3
(CD27, CD11bþ), that represent NK cells at distinct devel-
opmental stages [26,27]. R1 cells are immature, whereas R2
and R3 fractionate the mature cells into two populations.
While adoptively transferred R2 cells can differentiate into
R3 cells, R3 cells appear to be terminally differentiated. We,
Table 1. NK Cells Are Required for Resistance to Mousepox during Early ECTV Infection
Mice Intact B6 Mice NK Cell–Depleted B6 Mice
Anti-asialo GM1 Anti-NK1.1
Days PI Days PI
0 2 4 6 0 2 4 6
Dead/Total 0/60 6/6 6/6 6/6 0/6 15/16 13/16 12/15 0/6
Time of death (Days PI) N/A 9–10 9–10 9–11 N/A 7–10 8–11 8–11 N/A
Mortality rate 0% 100% 100% 100% 0% 94% 81% 75% 0%
B6 mice were infected with 3,000 pfu ECTV and depleted of NK cells on the indicated days PI with either anti-asialo GM1 or anti-NK1.1 and survival was monitored. N/A, not applicable.
There was statistically significant difference (p , 0.0001 in all cases, Log Rank Test) between intact mice and NK-depleted mice with either Ab on or before day 4 PI.
doi:10.1371/journal.ppat.0040030.t001
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Author Summary
Ectromelia virus (ECTV) causes mousepox, a murine disease that is
the equivalent of human smallpox. ECTV normally penetrates
through the periphery but rapidly spreads through the lymphatic
system to vital organs. In mousepox-sensitive strains of mice, ECTV
infection culminates with either rapid death or overt symptoms of
mousepox due to very high loads that the virus reaches in vital
organs, particularly the liver. However, some strains of mice such as
C57BL/6 (B6) and 129 also become infected with ECTV but naturally
resist mousepox by controlling the virus loads in vital organs and
clearing the virus without clinical symptoms of disease. Natural killer
(NK) cells are cells of the innate immune system previously shown to
play an important role in natural resistance to mousepox. However,
how NK cells protect from this disease is still unknown. In this paper
we show that NK cells directly contribute to antiviral defenses by
curbing virus dissemination to vital organs and also indirectly by
augmenting the antiviral T cell response. We also demonstrate that
optimal protection requires the activating NK cell receptor NKG2D
which facilitates killing of ECTV-infected cells. Our work has
important implications for the understanding of natural resistance
to viral disease.
therefore, investigated whether ECTV infection altered the
maturation phenotype of NK cells in the D-LN and found a
substantial increase in NK cells with a mature (R3) phenotype
on day 2 PI (Figure 1F, upper panels). Of interest, the
majority of effectors (IFN-cþ and/or GzBþ) were within this
mature NK cell population (Figure 1F, lower panels).
Together, these data demonstrate that the increased NK cell
number in the D-LN at early time points PI is mainly a result
of recruitment. Moreover, the data show that the NK cells
responding to ECTV infection are mature or mature very
rapidly after infection.
Control of Early Virus Dissemination by NK Cells Is
Dependent on IFN-c and Perforin
We hypothesized that the observed early recruitment to
and activation of NK cells in the D-LN may contribute to the
prevention of virus dissemination to central organs. Thus, we
depleted NK cells in B6 mice with anti-NK1.1 mAb (PK136)
and determined viral titers in spleen and liver on day 3 PI. To
rule out a role for T cells at this stage we also depleted both
CD4þ and CD8þ T cells by using a combination of anti-CD4
(GK1.5) and anti-CD8 (2.43) mAbs. Depletion of NK cells
resulted in .103-fold increase in viral loads in the spleen,
while a much lower increase in virus titers was observed in
mice depleted of T cells. The slight increase in virus titers in
the T cell–depleted mice was not statistically significant (p ¼
0.09) and was not reproducible. We also observed a significant
increase in virus titers on day 3 PI in the livers of NK cell–
depleted mice, but not T cell–depleted mice (p¼ 0.07) (Figure
1G). Therefore, NK cells, and not T cells, are responsible for
limiting the early dissemination of ECTV from the site of
infection to central organs.
NK cells can control viral infections by producing antiviral
cytokines, such as IFN-c, or by perforin (Pf)-mediated killing
of infected cells [28]. Others have shown that B6 mice
deficient in either Pf or IFN-c are susceptible to mousepox
[29,30]. However, whether the early control of virus dissem-
ination (day 3 PI) by NK cells requires IFN-c and/or Pf-
Figure 1. The Rapid Kinetics of the NK Cell Response Controls the Early
Dissemination of ECTV to Central Organs by Using IFN-c- and Perforin-
Dependent Mechanisms
Intact or NK cell–depleted (treated with anti-NK1.1 mAb PK136) B6 mice
were infected with 3,000 pfu ECTV. (A) 7 d PI, the absolute numbers of
live lymphocytes in the spleen were determined by trypan blue
exclusion. Data correspond to the average 6 SD of pooled spleens of
three mice from five independent experiments.
(B) 7 d PI, virus titers in spleen and liver were determined by plaque
assay. Data correspond to the average 6 SD of six individual mice from
two independent experiments.
(C) B6 mice were infected with ECTV in the footpad. The NK cell
response, as determined by the percentage of NK cells expressing
intracellular IFN-c, at the indicated times PI was determined in the
indicated organs. Data correspond to pools of three mice and are
representative of three similar experiments.
(D) Representative flow cytometric analysis of D-LN from mice infected
for 2 d with ECTV and from control uninfected mice. Upper panel: Dot
plots indicating the proportion of NK cells (NK1.1þ, CD3e). Lower panel:
GzB and IFN-c production by gated NK cells (NK1.1þ/CD3e gate of the
upper panels). Data correspond to pools of three mice and are
representative of at least five experiments. .98% of cells stained with
control Ig were in the lower left quadrant of the dot plots (not shown).
(E) B6 mice were infected with ECTV, and NK cell (NK1.1þ, CD3e)
proliferation was determined at different times PI in the indicated organs
by using a 3-h BrdU incorporation assay. Data are representative of three
independent experiments.
(F) Flow cytometric analysis of D-LN from mice infected for 2 d with ECTV
and from control uninfected mice. Upper panels: Plots are gated on NK
cells (NK1.1þ, CD3e). Lower panels: Gated on R1, R2, and R3 populations
from the upper-right (infected) plot. Data are representative of three
independent experiments.
(G) Intact B6 mice and B6 mice depleted of NK cells (treated with anti-
NK1.1) or T cells (treated with anti-CD4 and anti-CD8) were infected with
ECTV and virus titers in spleen and liver were determined on day 3 PI.
Data are the average 6 SD of six individual mice from two experiments.
(H) Wild-type and IFN-c-deficient B6 mice were infected with ECTV in the
footpad, and virus titers were determined 3 d PI. Data are the average 6
SD of three individual mice and is representative of two individual
experiments.
(I) Wild-type and Pf-deficient B6 mice were infected with ECTV in the
footpad and virus titers were determined 3 d PI. Data are the average 6
SD of three individual mice and are representative of two individual
experiments.
doi:10.1371/journal.ppat.0040030.g001
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mediated killing is unknown. We, therefore, compared virus
titers on day 3 PI in the spleens of wild-type (WT), IFN-c-
deficient, and Pf-deficient B6 mice. We found that both IFN-
c-(Figure 1H) and Pf-deficient mice (Figure 1I) had signifi-
cantly elevated virus titers as compared to B6 mice. Thus, the
early control of virus dissemination by NK cells requires both
the antiviral effects of IFN-c and Pf-mediated cytotoxicity.
Reduced T Cell Response in the Absence of NK Cells
Our previous studies and those of others showed that an
optimal CD8þ T cell response is required for resistance to
mousepox [8,25,31]. The data above indicate that NK cells
have a direct effect in preventing mousepox by curbing virus
dissemination during early infection. However, NK depletion
at early stages resulted in an increase in spleen and liver viral
titers, splenic lymphopenia, liver pathology, and death on day
7 PI (Figure 1 and Table 1), a time when the presence of NK
cells was no longer necessary (Table 1) and when the T cell
response should have already peaked [25]. This suggested that
the absence of NK cells may have an impact on the
establishment of the adaptive anti-ECTV T cell response.
Thus, we compared in vivo T cell proliferation in intact mice
and mice depleted of NK cells on day 0 PI. We found that on
day 5 PI (when the T cell response normally peaks in D-LN),
only a few CD8þ and CD4þ T cells incorporated BrdU in the
D-LN of NK cell–depleted mice, while ;40% of CD8þ T cells
and 20% of CD4þ T cells incorporated BrdU in intact mice
(Figure 2A). Mice depleted of NK cells on day 0 PI also had
substantially reduced T cell proliferation in spleen and liver
on day 7 PI (the time when the T cell response normally peaks
in the spleen, data not shown). We also determined the CD8þ
T cell response by intracellular staining for the effector
molecules, GzB and IFN-c. On 7 d PI, there was a strong T cell
response in spleen with;70% of CD8þT cells producing GzB
and more than 10% of CD8þT cells producing IFN-c in intact
B6 mice (Figure 2B). However, in mice depleted of NK cells
on day 0 PI, the CD8þ T cell response was greatly reduced,
with only ;30% of CD8þ T cells producing GzB and ;5%
CD8þT cells producing IFN-c. Furthermore, because infected
NK cell–depleted mice had severely lymphopenic spleens
(Figure 1A), they also had a 16-fold reduction in the absolute
number of effector CD8þ T cells as compared with infected
intact mice (data not shown). These results indicate that the
adaptive T cell response was substantially reduced in the
absence of NK cells.
Resistance to Mousepox Involves the Activating Receptor
NKG2D but Not NK1.1
To gain insight into the mechanism whereby NK cells
become activated during ECTV infection, we explored
whether various known NK cell–activating receptors are
involved in resistance to mousepox. We first focused on
NK1.1 and on the activating receptors of the Ly49 family. We
focused on these receptors because NK1.1 is not encoded in
mousepox-susceptible DBA/2 and BALB/c mice. Furthermore,
it has been speculated that NK1.1 might be Rmp1 [24]. In
addition, there is good precedent for the involvement of
Ly49H in NK cell–mediated antiviral responses, more
specifically to MCMV [20–22]. Ly49D and Ly49H are the only
activating receptors of the Ly49 family in B6 mice. Because
B6 mice selectively deficient in NK1.1, Ly49H, or Ly49D are
not available, we first used 129/Sve mice, which do not express
any of these receptors [22]. Similar to B6 mice, 129/Sve mice
were naturally resistant to mousepox but became sensitive
when depleted of NK cells with anti-asialo GM1 Ab (PK136
could not be used because 129/Sve mice do not express
NK1.1) (Table 2). This demonstrates that NK cells are also
required for 129/Sve mice resistance to mousepox but that
NK1.1, Ly49D, or Ly49H are not essential for resistance
because 129/Sve do not possess these receptors.
The results above suggested, but did not formally prove
that Ly49H, Ly49D, and/or NK1.1 are not required for the
resistance of B6 mice to mousepox, because it remained
possible that Ly49H, Ly49D, and/or NK1.1 play a role in B6
resistance but that other activating receptors substitute their
function in 129/Sve mice. Although it is not possible to
definitively rule out the participation Ly49H or Ly49D in B6
resistance with currently available reagents, we took advant-
age of FceRIc-deficient B6 mice [32] to rule out a role for
NK1.1. It is known that NK1.1 signaling requires association
with the ITAM-containing FceRIc adapter [33]. FceRIc-
deficient B6 mice, however, were completely resistant to
mousepox (Table 2), demonstrating that NK1.1 is not
essential for the resistance of B6 mice to mousepox. In
addition, because Abs are required for long-term resistance
to mousepox [8,31] and FceRIc is required for Ab-dependent
cellular cytotoxicity (ADCC) [32], these data also demonstrate
that ADCC is not involved in Ab-dependent resistance to
mousepox.
We addressed whether the activating receptor NKG2D
might be involved in mousepox resistance. NKG2D is
Figure 2. Reduced T Cell Responses in the Absence of NK Cells
(A) Intact or NK cell–depleted B6 mice were infected with 3,000 pfu ECTV.
T cell proliferation on day 5 PI was determined in the D-LN by using a 3-h
BrdU incorporation assay. Upper panel: gated on CD8þ T cells; lower
panel: gated on CD4þ T cells.
(B) Intact or NK cell–depleted B6 mice were infected with ECTV.
Production of IFN-c and GzB by CD8þ T cells in spleen on day 7 PI was
determined. Plots are gated on CD8þ T cells. Data are representative of
three independent experiments.
doi:10.1371/journal.ppat.0040030.g002
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expressed by NK cells and some T cells, including cd-TcRþ T
cells and activated CD8þ T cells. Although not polymorphic,
this activating receptor is expressed at somewhat lower levels
on activated NK cells of mousepox-susceptible NOD and
BALB/c mice than in B6 mice ([34] and unpublished data).
Because NKG2D-deficient mice are not available, we took
advantage of the anti-NKG2D mAb CX5 that, in vivo, blocks
binding of NKG2D to its ligands and causes its internalization
without depleting NKG2D-bearing cells [35–37]. We inocu-
lated B6 mice with CX5 mAb or control rat IgG 1 d before
and 2 d PI. As shown in Table 2, CX5 treatment resulted in
50% mortality suggesting that NKG2D is involved in the NK
cell–mediated resistance to mousepox.
In mice, NKG2D signals through either DAP10 or DAP12
adapter proteins, whereas Ly49H and D signal through
DAP12 [38–40]; therefore, we determined mousepox suscept-
ibility in either DAP12- or DAP10-deficient mice on a B6
mousepox-resistant background. We found that more than
50% of DAP12-deficient mice developed the typical skin rash,
but only 10% died following ECTV infection, whereas all
DAP10-deficient mice survived without showing ostensible
symptoms of mousepox (Table 2).
To get further insights into the role of NKG2D and its
adapters in resistance to mousepox, we determined cell
numbers and virus titers 7 d PI in NKG2D-blocked as well as
in DAP12- and DAP10-deficient mice. Results showed that
NKG2D blockade and DAP12- or DAP10-deficiency resulted
in significantly decreased splenic lymphocytosis as compared
with wild type, untreated B6 mice (Figure 3A). More
important, the viral loads in NKG2D-blocked mice were
almost 103 times higher than in unblocked mice, whereas
those of DAP12- and DAP10-deficient mice were also
significantly elevated, but to a lesser degree (102 and 10 times
higher, respectively) (Figure 3B). Thus, the degree of splenic
lymphocytosis and viral loads on day 7 PI was consistent with
the lethality and symptoms of mousepox that we observed
under the different conditions. Together, these results show
that NKG2D is involved in resistance to mousepox. The data
also suggest that for this process NKG2D preferentially, but
not exclusively, uses DAP12 as the signaling adapter. Most
likely, the absence of one adapter is partially compensated by
the presence of the other. The data further suggest that
Ly49H and Ly49D are not essential for B6 resistance to
mousepox because DAP12-deficient mice were only mildly
susceptible to mousepox infection. This contrasts with prior
studies demonstrating that DAP12-deficient mice on a B6
MCMV-resistant background are exquisitely sensitive to
MCMV infection [41].
NK Cells Require NKG2D to Control Early Virus
Dissemination and to Mediate Optimal Cytotoxicity
NKG2D is expressed by NK cells [42] and its expression is
further increased during MCMV infection (J. Sun and L. L.
Lanier, unpublished data). We, therefore, determined
whether ECTV infection also increased NKG2D expression
on NK cells. As shown in Figure 4A, NK cells increased
NKG2D expression at the cell surface, and the proliferating
NK cells after ECTV infection were NKG2Dhigh.
The data above showed that NK cells are the main
population-controlling early virus dissemination to visceral
organs, and that absence of NKG2D signaling results in
increased susceptibility to mousepox. However, NKG2D is
not only expressed by NK cells but also by some T cells. We
hypothesized that if NKG2D has a role in NK cell–mediated
resistance to mousepox, NKG2D blockade should result in
increased early virus dissemination to organs independent of
T cells. To test this hypothesis, we measured early viral titers
Table 2. NKG2D Is Involved in NK Cell–Mediated Resistance to Mousepox
Mice FccRIe0/0 129/Sve 129/Sve NK Cell–Depleted B6 / NKG2D-Blocked B6 / Mock-Blocked DAP100/0 DAP120/0
Disease/total 0/12 0/25 13/17 14/20 0/8 0/18 10/18
Disease rate 0% 0% 76.5% 70% 0% 0% 56%
Death/total 0/12 0/25 13/17 11/20 0/8 0/18 2/18
Mortality rate 0% 0% 76.5% 55% 0% 0% 11%
Indicated mice were infected with 3,000 pfu ECTV, and the disease and death were observed daily over time. There was statistically significant difference for survival between 129/Sve mice
and anti-asialo GM1 NK-depleted 129/Sve mice (p , 0.00001, Log Rank Test) and between NKG2D-blocked mice and the mock-blocked mice (p ¼ 0.0119, Log Rank Test) in terms of
survival. There was also significant difference (p , 0.00001, Log Rank Test) for disease between B6 (in Table 1) and DAP12-deficient mice.
doi:10.1371/journal.ppat.0040030.t002
Figure 3. NKG2D Uses DAP10 or DAP12 Adapters to Help Resist
Mousepox
(A) The indicated mice were infected with 3,000 pfu ECTV and the
absolute number of lymphocytes in their spleens was determined on day
7 PI by trypan blue exclusion. An uninfected control is also shown. Data
are the average6 SD of three pooled mice per group from at least three
individual experiments.
(B) Virus titers in spleen of the indicated mice on day 7 PI. Data are the
average 6 SD of three pooled mice per group from at least three
individual experiments.
doi:10.1371/journal.ppat.0040030.g003
PLoS Pathogens | www.plospathogens.org February 2008 | Volume 4 | Issue 2 | e300005
NKG2D in Resistance to Mousepox
in the spleens (day 3 PI) of mice treated with the anti-NKG2D
mAb CX5. To rule out a role of NKG2D on T cells at this time,
we also included groups of mice that were T cell–depleted or
NKG2D-blocked and T cell–depleted. As shown in Figure 4B,
NKG2D-blocked and T cell–depletedþNKG2D-blocked mice
had virus titers that were comparable to those of NK cell–
depleted mice and that were significantly higher than those of
mice that were only T cell–depleted. Together, these data
indicate that NKG2D is involved in the NK cell–mediated
resistant to mousepox.
We next tested whether NKG2D blockade and DAP10- or
DAP12-deficiency affected the recruitment of NK cells to D-
LN (Figure 4C, upper panels) or their ability to produce IFN-
c and GzB (Figure 4C, lower panels). However, we found that
none of these parameters were decreased. In fact, in both
DAP10- and DAP12-deficient mice more NK cells were
recruited to the D-LN and a larger proportion produced
IFN-c and GzB as compared with wild-type B6 mice. This
indicates that NKG2D is required for effective NK cell–
mediated control of ECTV, but is not required for their
activation.
Because NK cell recruitment and activation in the D-LN
was not diminished by NKG2D blockade or DAP12 and
DAP10 deficiency (Figure 4C), we hypothesized that NKG2D
may be required for optimal NK cell–mediated cytotoxicity.
Thus, we examined whether NK cells from NKG2D-blocked
mice were defective in their ability to kill various targets. For
this purpose, mice were infected with ECTV and treated or
not with anti-NKG2D Ab. Five days later, NK cells were
purified from their spleens and immediately analyzed by flow
cytometry to confirm NKG2D receptor blockade or down-
regulation in the CX5-treated mice (Figure 4D) and were used
as effectors in 4-h 51Cr release assays. Because we were unable
to show specific killing of ECTV-infected cells in vitro, we
tested the purified NK cells against a variety of uninfected
Figure 4. NK Cells Require NKG2D to Control Early Virus Dissemination
and for Optimal Cytotoxicity but Not Activation
(A) B6 mice were infected with 3,000 pfu ECTV. On day 5 PI, mice were
pulsed with BrdU for 3 h and their spleens analyzed by flow cytometry.
Plots are gated on CD3e NK1.1þ cells. Data correspond to pools of three
mice from three individual experiments.
(B) Increased viral titers of infected mice with NKG2D blockade in vivo.
Intact B6 mice, B6 mice with NKG2D blockade, B6 mice depleted of NK
cells, B6 mice depleted of T cells (treated with anti-CD4 þ anti-CD8
mAbs), or depleted of T cells and with NKG2D blockade were infected
with 3,000 pfu ECTV and the viral titers in spleen were determined on
day 3 PI. Data are the average 6 SD of three individual mice and are
representative of two similar experiments.
(C) The indicated mice were infected with 3,000 pfu ECTV, and the NK
responses in the D-LN were determined at 2 d PI. Upper panel: Dot plot
showing the proportion of NK cells (DX5þ, CD3e) in the D-LN of infected
and control uninfected mice. Lower panel: GzB and IFN-c production by
NK cells. Cells correspond to the DX5þ, CD3e gate of the upper panels.
Data correspond to pools of three mice and are representative of three
similar experiments.
(D) NK cells were purified from spleens (5 d PI) of ECTV-infected intact or
NKG2D-blocked mice and stained as indicated. Filled histogram: isotype-
matched control Ig; gray line: NKG2D-blocked mice; black line: intact
mice.
(E) NK cells were purified from spleens of intact or NKG2D-blocked mice
as indicated and were used as effectors in a 4-h 51Cr release assay against
the indicated targets. Data correspond to pools of three mice and are
representative of three experiments.
(F) As in (D), but the NK cells were purified from untreated mice and a
neutralizing anti-NKG2D mAb was added to the in vitro cytotoxicity
assays, as indicated.
doi:10.1371/journal.ppat.0040030.g004
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targets that constitutively express NKG2D ligands at their cell
surface (MC57G, MEF, and YAC-1) or, as a control, CHO-K1
whose killing is dependent on Ly49D [43,44], but not NKG2D.
We found that the NK cells from mice infected with ECTV
(whether treated with anti-NKG2D Ab or not) killed all
targets much more effectively than those from uninfected
mice. This enhanced killing did not require the targets to be
infected. However, the NK cells from mice treated with CX5
were less effective killers of NKG2D ligand-bearing target
cells as compared to those from untreated mice, except
against CHO-K1 cells for which the NK cell killing is
dependent on Ly49D and not on NKG2D (Figure 4E).
Furthermore, purified NK cells from ECTV-infected intact
mice also demonstrated reduced, but not absent cytotoxicity
when anti-NKG2D mAb was added to the assay (Figure 4F).
Thus, ECTV infection enhances spontaneous NK cell–
mediated cytotoxicity, which is partially reduced by NKG2D
blockade. Together, these data suggest that NKG2D signaling
is not required for the recruitment and activation of NK cells
during ECTV infection, but contributes to their optimal
ability to kill targets expressing NKG2D ligands. Because anti-
NKG2D did not reduce cytotoxicity to the same levels as
those in uninfected mice, the data also indicate that
activating receptors other than NKG2D are involved in the
cytotoxicity induced by ECTV infection.
ECTV Infection Upregulates NKG2D Ligands In Vitro and In
Vivo
NKG2D-mediated killing requires the recognition of
ligands on the surface of target cells. The ligands of NKG2D
are host cell–encoded MHC class I–like proteins that are
expressed by tumors and stressed cells and also following
infection of cells with some viruses. Identified cellular ligands
for NKG2D in mice include H60, MULT1, and Rae-1 [45–49].
To determine if ECTV infection induces the upregulation of
NKG2D ligands, we infected mouse embryo fibroblasts (MEFs)
with 0.5 pfu/cell ECTV expressing enhanced green fluores-
cence protein (EGFP), and the expression of NKG2D ligands
on infected and uninfected cells was determined by flow
cytometry. Consistent with the ability of ECTV-activated NK
cells to spontaneously kill them, MEFs constitutively express
NKG2D ligands as revealed by staining with mouse NKG2D-
Fc fusion protein [50] (Figure 5A). However, infection with
ECTV increased NKG2D-Fc staining and resulted in clear
upregulation of MULT1 (Figure 5A) but not Rae-1 (data not
shown). We also observed increased staining with NKG2D-Fc
and anti-pan Rae-1 and anti-MULT1 mAbs in the fibrosarco-
ma cell line MC57G, and an increase in staining with NKG2D-
Fc and anti-pan Rae-1 mAb in peritoneal lymphocytes (data
not shown). Moreover, using quantitative RT-PCR, we
detected a 2.8-fold increase of Rae-1 transcripts in the D-
LN of ECTV-infected mice at 12 h PI, as compared with
uninfected controls (Figure 5C). Thus, these results show that
ECTV infection can induce the expression of NKG2D ligands,
suggesting that binding of NKG2D with these ligands might
result in improved NK cell killing of infected cells in vivo and
better control of ECTV dissemination.
Discussion
In this study, we confirmed previous reports demonstrating
that NK cells are required for natural resistance to mousepox
[15–17]. More importantly, we define several of the mecha-
nisms whereby NK cells afford this resistance.
To determine whether and when NK cells are required for
resistance to mousepox we depleted mice of NK cells with
either anti-asialo GM1 or anti-NK1.1 Abs at different times
PI. Although separately these two approaches have caveats,
together they provide conclusive evidence that the presence
of NK cells during the first 4 d PI, but not beyond day 5 PI, is
essential for resistance to mousepox. First, even though anti-
NK1.1 Ab depletes NKT cells, the loss of mousepox resistance
upon Ab treatment cannot be due to the elimination of NKT
cells because anti-asialo GM1 Ab does not eliminate this
population [51,52]. Furthermore, Parker et al. recently
demonstrated that NKT cells are dispensable for resistance
to mousepox because ECTV infection of mice deficient in
NKT cells (i.e., CD1d- and Va14Ja281 TCR-deficient mice) did
not result in symptoms of mousepox or an increase in virus
titers when compared to wild-type B6 mice [17]. Second,
although anti-asialo GM1 can eliminate some activated T cells
[53], the loss of resistance cannot be attributed to T cell
depletion because asialo GM1 is not expressed on virus-
specific T cells within the first few days after viral infection.
Figure 5. ECTV Infection Induces Increased Expression of NKG2D Ligands
In Vitro and In Vivo
(A) MEFs were infected with 0.5 pfu ECTV 189898-p7.5-EGFP for 18 h.
Cells were analyzed for staining with the indicated reagents after gating
for EGFP cells (uninfected) and EGFPþ cells (infected). Data correspond
to one typical experiment from three similar experiments. Shaded area,
infected cells stained with isotype-matched control Ig or secondary Ab
alone; black line, infected cells stained with the indicated reagent; gray
line, non-infected cells stained with the indicated reagent.
(B) qRT-PCR was performed as described. Data were normalized to the
amount of b-actin mRNA. Data are representative of two similar
experiments.
doi:10.1371/journal.ppat.0040030.g005
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Moreover, we show that anti-NK1.1 and -asialo GM1 Abs do
not affect resistance when given on day 6 PI (the peak of the T
cell response). Furthermore, treatment with anti-NK1.1, but
not depletion of T cells one day before infection, resulted in
significantly increased virus titers on day 3 PI. In addition,
treatment with anti-asialo GM1 Ab accelerated ECTV lethal-
ity in RAG-1-deficient mice, which lack adaptive immunity
(data not shown). cd T cell–deficient mice are also resistant to
mousepox [17], indicating that the possible depletion of some
cd T cells by anti-asialo GM1 Ab cannot account for the
dramatic increase in ECTV lethality after treatment with this
Ab. Although work in other laboratories has already shown
that depletion of NK cells with either anti-NK1.1 or asialo-
GM1 results in susceptibility to mousepox [6,15,17], depletion
at different times PI has not been described previously.
Sequential depletion of NK cells allowed us to establish that
the presence of NK cells is required only during the very early
stages of infection. This is consistent with the concept that
NK cells serve as the first line of defense after infection,
thereby providing sufficient time to mount a full-fledged T
and B cell response. We also established, however, that the
contribution of NK cells to mousepox resistance extends
beyond the need for their physical presence to kill virus-
infected cells early after infection because NK cell depletion
before day 4 PI resulted in higher virus titers and death after
this time. This is most likely due to the role of NK cells in
allowing a potent antiviral T cell response to develop, as
discussed below.
We also followed the kinetics of NK proliferation and
activation in spleen, liver, and D-LN of ECTV-infected mice.
Interestingly, although we detected some proliferation, we
did not find activated NK cells in liver and spleen on day 3 PI.
This was despite the fact that NK cell–mediated control of
virus loads in spleen and liver already occurred at this time
PI. In fact, the peak of NK cell activation in spleen and liver
took place on day 5 PI. On the other hand, the proportion of
total NK cells, as well as the proportion of activated NK cells
in the D-LN, peaked as early as day 2 PI, and these parameters
were still substantially elevated on day 3 PI, notwithstanding
that the proliferation of NK cells at these times was not yet
detectable in D-LN. In addition, we found that the increase in
NK cell numbers in the D-LN on day 2 PI was mostly due to
an increase in mature NK cells and that these mature NK cells
were preferentially activated. Together, these data suggest
that the prompt NK cell response in the D-LN is responsible
for the early control of virus loads in central organs and that
this response is mostly due to the recruitment and activation
of mature NK cells rather than their expansion. To spread to
central organs from the footpad, ECTV must pass through the
D-LN [5,54–56]. Recently, we have shown that in mousepox-
susceptible BALB/c mice, memory CD8þ T cells protect from
mousepox, at least in part, by curbing the spread of ECTV
from the D-LN to central organs and allowing for the
establishment of a full-fledged adaptive response [54]. Our
results here suggest that NK cells may use the same strategy,
furthering a model where LNs are not only sites where
lymphocytes are primed and proliferate but also the place
where a major fight against virus spread takes place [54].
In addition to NK cells, strong adaptive T cell responses are
essential for resistance to mousepox. Our experiments here
show that NK cells have a direct role in controlling ECTV
because they reduced virus loads on day 3 PI when the T cell
response is still undetectable (data not shown and [25]).
However, if the only role of NK cells were direct, one would
expect mice depleted of NK cells to become sick, but recover
once the adaptive immune system takes control. Yet, while
the presence of NK cells on day 6 PI was not required for
resistance to mousepox, their presence before day 6 PI was
vital for controlling virus titers and preventing pathology and
death after this time. This could be explained by the finding
that depletion of NK cells on the day of infection resulted in a
substantially reduced T cell response. There are three non-
excluding possibilities that may explain this effect. First, NK
cell production of cytokines such as IFN-c may directly
modulate the adaptive T cell response [28]. A caveat to this
hypothesis is that NK cells produce as much or more IFN-c in
ECTV-infected mousepox-susceptible BALB/c and DBA2/J
mice as in resistant B6 mice (unpublished data), but these
susceptible mice fail to mount an effective T cell response to
ECTV. Second, NK cells may indirectly affect the activation of
T cells through their interaction with antigen-presenting cells
such as macrophages and dendritic cells (DC). This hypothesis
has the same caveats as the one above. Third, it is possible
that in the absence of NK cells, the uncontrolled virus
replication of a highly pathogenic virus overwhelms the T cell
response. In support of this possibility, infection of mouse-
pox-susceptible BALB/c mice with a highly attenuated strain
of ECTV results in the induction of a strong T cell response
(unpublished data), and depletion of NK cells does not affect
the T cell response to the poorly pathogenic vaccinia virus
(unpublished data) with which ECTV shares most of the
dominant CD8þ T cell epitopes [57].
Previous work by Delano and Brownstein showed that
Rmp1, a gene important for resistance to mousepox, maps to
the NK complex in distal chromosome 6 [16]. Moreover, they
proposed that Rmp1 encoded NK1.1 [24]. However, we found
that NK1.1 is not required for resistance to mousepox. In
addition, our work suggests that the activating receptors
Ly49D and Ly49H are likely not involved. On the other hand,
using in vivo signaling blockade we found that NKG2D is
involved in resistance to mousepox and that ECTV infection
results in the upregulation of NKG2D ligands in vivo and in
vitro. That NKG2D is involved in antiviral responses has
precedents. For example, previous studies have shown that
cytomegalovirus (CMV) induces the upregulation of NKG2D
ligands and that mouse and human CMV encode immune
evasion molecules that downregulate NKG2D ligands and are
important for their pathogenesis [28]. However, a direct role
for NKG2D in the response to poxviruses has not been
described previously. Interestingly, Campbell et al. have
recently shown that cowpox virus encodes a soluble com-
petitive antagonist of NKG2D [58]. Although this gene has
been lost in other OPVs, such as ECTV, VACV, VARV, and
MPXV, these data support our finding that NKG2D is
involved in resistance to some OPV infections. On the other
hand, NKp30, NKp44, and NKp46, but not NKG2D, were
found to be responsible for the recognition of VACV-
infected cells by human NK cells [59]. Whether this reflects
differences between NK cell recognition of different OPVs,
differences between human versus mouse NK cells, or both,
will require further investigation.
Because mouse NKG2D signals through either the adapter
protein DAP12 or DAP10, we further tested the susceptibility
of mice lacking one or the other adapter. Of interest, when
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considering virus titers and spleen cellularity, the suscepti-
bility of these two strains of mice was intermediate between
intact and NKG2D mAb–blocked B6 mice. This indicates that
for resistance to mousepox, the two adapters likely have
overlapping, but not completely redundant, effects. Still,
DAP12 seems to be the preferred adapter because DAP12-
deficient mice were more susceptible to mousepox than
DAP10-deficient mice, although it is possible that other
DAP12-associated receptors might contribute to resistance to
mousepox. Our results predict that DAP10þ DAP12 double-
deficient mice would be highly susceptible to mousepox.
Unfortunately, these mice are not yet available.
NKG2D is expressed by most NK cells but also by activated
CD8þ T cells. In fact, we have observed that in ECTV-infected
B6 mice a large proportion of virus-specific CD8þ T cells
express NKG2D beginning 7 d PI (unpublished data). Thus,
the experiments reported here do not rule out the additional
contribution of NKG2D in the T cell–mediated resistance to
mousepox, a very interesting possibility that we are currently
investigating. Nevertheless, our experiments clearly implicate
NKG2D in the NK cell–mediated response to ECTV because
in vivo NKG2D blockade resulted in enhanced virus loads in
central organs before the onset of the T cell response and
because in vivo NKG2D blockade reduced the cytotoxicity of
ECTV-activated NK cells. Still, several lines of evidence
indicate that NKG2D is not the only activating receptor
involved in the anti-ECTV NK cell–mediated response and
that its most likely role is as a co-stimulator that facilitates
cytotoxicity rather than being required for the initial NK cell
activation: (1) NK cell depletion was much more effective
than NKG2D blockade at rendering B6 mice susceptible to
mousepox; (2) NKG2D-blockade did not affect NK cell
proliferation (data not shown), IFN-c and GzB production
by NK cells, or recruitment of NK cells into the D-LN of
ECTV-infected mice; (3) In vivo and in vitro NKG2D blockade
significantly decreased, but did not abrogate, the cytotoxicity
of ECTV-activated NK cells. Ongoing studies in our labo-
ratory are aimed at identifying other activating receptor(s)
and signaling pathway(s) required for NK cell–mediated
resistance to mousepox.
In summary, our work demonstrates that NK cells contrib-
ute to the natural resistance of B6 mice to mousepox by using
direct effector functions (most likely the killing of infected
cells) to curb virus dissemination and by supporting a strong
adaptive T cell response. Moreover, our data suggest that the
activating receptor NKG2D, but not NK1.1 or Ly49 family
members, has a role in this NK cell–mediated resistance to
mousepox by promoting optimal NK cell–mediated killing.
Thus, our data provide substantial insights into the mecha-
nisms of natural resistance to ECTV and possibly other OPV
infections. Together, our work furthers our understanding of
host-pathogen interactions and the mechanisms whereby NK
cells protect from viral disease.
Materials and Methods
Cells. YAC-1 and CHO-K1 cell lines were obtained from Dr. Kerry
Campbell (Fox Chase Cancer Center, Philadelphia, Pennsylvania), and
A9, MC57G, and BSC-1 cells were obtained from the ATCC. MEF cells
were made from day 11 to 13 embryos from B6 mice. As standard
tissue culture media, we used RPMI-10 that consisted of RPMI-1640
medium (Invitrogen) supplemented with 10% fetal calf serum
(Sigma), 100 IU/ml penicillin and 100 lg/ml streptomycin (Invitro-
gen), 10 mM Hepes buffer (Invitrogen), and 0.05 mM 2-mercaptoe-
thanol (Sigma). MEF were grown in DMEM medium containing 15%
fetal calf serum. When indicated, RPMI 2.5 (as above but with 2.5%
FCS) was used. When required, 10 U/ml interleukin 2 (IL2) was added
to RPMI 10 (RPMI 10-IL2). All cells were grown at 37 8C and 5% CO2.
Viruses, mice, and infections. The production of ECTV stocks for
infection of mice and the determination of titers in stocks and organs
were done as described previously [8]. To generate ECTV 189898-
p7.5-EGFP, we adapted the method described by Johnston and
McFadden [60]. Briefly, a construct containing the ECTV Moscow
fragment 189543–189897, the VACV early/late promoter p7.5, the
sequence of EGFP, and the ECTV Moscow fragment 189950–190297,
in that order, was made by recombinant PCR and cloned into plasmid
Bluescript II SKþ to generate the targeting vector pBS-EVM189898-
p7.5-EGFP. This targeting vector was used to transfect mouse A9 cells
using Lipofectamine 2000 as per manufacturer’s instructions (Invi-
trogen). The transfected cells were infected with wild-type ECTV
(Moscow strain, 0.3 pfu/cell) in 6-well plates. 2 d later, transfected/
infected A9 cells were harvested using a rubber policeman, frozen
and thawed, and different dilutions of cell lysates were used to infect
BSC-1 cells in 6-well plates. 2 h after infection, the cells were overlaid
with media containing 0.5% agarose. 4 d later, green-fluorescent
plaques were picked with a pipette tip and used to infect a new set of
cells. The purification procedure was iterated five times until all
plaques were fluorescent. The resulting virus, ECTV 189898-p7.5-
EGFP, carries EGFP in a non-coding region and is as pathogenic as
wild-type ECTV Moscow (not shown). For preparation of ECTV stock
for infection of different cell lines, A9 cells were infected with 0.2 pfu
ECTV/cell, and incubated at 37 8C, 5% CO2. After 5 d, the cells were
collected, frozen and thawed three times, and then sonicated in a
water-bath sonicator. The solid material was pelleted by centrifuga-
tion, and the supernatant was stored in aliquots at 80 8C. The
DAP10-deficient mice [61,62] (generously provided by Dr. Joe
Phillips) and DAP12-deficient mice [63] on the C57BL/6 background
were bred at UCSF. All the other mice were bred at the Fox Chase
Cancer Center Laboratory Animal Facility in specific pathogen-free
rooms or were purchased from Jackson Laboratories. IFN-c-deficient
C57BL/6 mice were generously provided by Dr. Glenn Rall. For
infections, sex-matched animals 8–12 wk old were transferred to a
biosafety level 3 room. For ECTV infection, anesthetized mice were
infected in the left footpad with 25 ll PBS containing 3 3 103 pfu
ECTV. Following infections, mice were observed daily for signs of
disease (lethargy, ruffled hair, weight loss, skin rash, and eye
secretions) and imminent death (unresponsiveness to touch and lack
of voluntary movements). Moribund mice were euthanized by
halothane inhalation. All of the experimental protocols involving
animals were approved by the Fox Chase Cancer Center Institutional
Animal Care and Use Committee.
For ECTV infection of cells, 3–5 3 105 cells were plated in 6-well
plates and cultured overnight to allow cells to adhere. The cells were
then infected with 0.5 pfu ECTV/cell for 18 h, collected, washed,
stained, and analyzed for surface expression of various markers. For
ECTV infection of peritoneal cells, the mice were euthanized by
halothane inhalation and injected i.p. with PBS, the abdomen
massaged gently, and the peritoneal cells were collected by aspiration
and washed.
In vivo depletion of NK cells or T cells and NKG2D blockade.
Depletion of NK cells was performed by i.p. inoculation of 200 lg
anti-NK1.1 mAb PK136 or 20 ll anti-asialo GM1 antisera (Wako), as
indicated. Antibody treatment was done 1 d before or on the
indicated days after virus infection. For depletion of T cells, mice
were injected i.p. with 200 lg anti-CD4 mAb GK1.5 and 200 lg anti-
CD8 mAb 2.43 1 d before infection. For NKG2D blockade mice were
inoculated with purified 200 lg CX5 Ab 1 d before and 2 d PI.
Isolation of liver lymphocytes. Mice were exsanguinated from the
orbital cavity to decrease the amount of blood in the liver. The liver
was removed and passed through a cell strainer (BD Falcon) to obtain
a single cell suspension. The cells were resuspended in 35% Percoll
solution (in PBS) containing 100 U/ml heparin and centrifuged at 830
3 g for 15 min at room temperature. The upper liquid phase was
removed from the tube, the lymphocyte pellet resuspended in 0.84%
NH4Cl solution to lyse the red blood cells, and then washed twice with
medium.
BrdU incorporation assay. At the indicated time post-infection
(PI), mice were injected with 2 mg BrdU i.p. 3 h later, spleens and
lymph nodes (LNs) were removed and made into single cell
suspensions. The liver lymphocytes were obtained as described above.
The cells were then stained for cell surface molecules, fixed, and
permeabilized using the Cytofix/Cytoperm kit (BD Pharmingen)
according to the manufacturer’s instructions, incubated with DNase
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at 37 8C for 1 h, and subsequently stained with FITC-conjugated anti-
BrdU mAb (eBiosciences).
Flow cytometry. Determination of cytokine production by intra-
cellular staining was done as described previously [8]. To determinate
NK cell responses in LNs, intact organs were incubated at 37 8C for 1
h in media containing 10 lg/ml brefeldin A, made into single cell
suspensions, stained, and analyzed as described above. To evaluate
NK cell responses in the spleen, the organs were made into single-cell
suspensions, RBC were lysed with 0.84% NH4Cl, and the lymphocytes
were washed and incubated at 37 8C for 1 h with brefeldin A, followed
by staining and analysis as described. To determine expression of
NKG2D ligands, MEFs were infected with 0.5 pfu ECTV 189898-p7.5-
EGFP for 18 h. Infected cells (;15%) were identified by EGFP
expression. Gated infected and uninfected cells were analyzed for
expression of NKG2D ligands by staining with: a PE-labeled rat anti-
mouse Rae-1 (IgG2a isotype, R&D Systems) or a PE-labeled rat
isotype-matched control IgG2a; with rat anti-mouse MULT1 (IgG2a
isotype, R&D Systems) and secondary PE-labeled donkey anti-rat
IgG2a or secondary Ab alone as a control; or with mouse NKG2D-
human Fc fusion protein (R&D Systems) and an APC-labeled anti-
human IgG (BD) secondary Ab or secondary Ab alone as control.
51Cr release assays. NK cells were purified from spleens using anti-
CD49b-conjugated microbeads and a LS column (Miltenyi Biotec)
according to the manufacturer’s instructions and were stained for
flow cytometric analysis with PE-conjugated anti-NKG2D mAb CX5.
NK cells were resuspended in RPMI 10, and serially diluted in round-
bottom 96-well plates in triplicate in 100 ll/well. The indicated target
cells were prepared by incubation with 200 ll 51Cr (0.1 mCi) in 100 ll
of FCS for 2 h. Cells were thoroughly washed, resuspended in RPMI
10, and 50 ll (53103 targets) were added to the wells containing
effector cells. The plates were incubated at 37 8C for 4 h. Where
indicated, 20 lg/ml of a neutralizing anti-NKG2D mAb (clone 191004,
R&D Systems) was added at the initiation of cytotoxicity assays. 50 ll
supernatants were transferred to white 96-well plates containing 75-
ll Microscint-40 scintillation fluid (PerkinElmer). Controls included
wells with target cells alone for spontaneous release and wells with
target cells and 1% Triton-X for maximal release. Radioactivity was
measured by using a Packard Topcount instrument (PerkinElmer).
Specific lysis was determined by using the formula [(experimental
release  spontaneous release)/(full release  spontaneous re-
lease)]3100. Three animals were used per experimental group.
Quantitative real-time PCR (qRT-PCR). Primers and probes for
Rae-1 were purchased from Applied Biosystems. The amplicon was 95
bp and the sequence of the probe was GGAAAAGCCAAGAT-
CAACCTCAAGG. The primers and probe for b-actin were synthe-
sized at the DNA Synthesis Facility in the Fox Chase Cancer Center.
The primers and probe used for b-actin were: sense, 59-CACC-
GAGGCCCCCCT-39; anti-sense, 59-CAGCCTGGATGGCTACGTACA-
39, and the probe was 59-6-FAM-AACCCTAAGGCCAACCGT-
GAAAAGATGA-BHQ1–39. Total RNA extracted from infected cell
lines and LNs of infected mice was treated with Dnase I, and the first-
strand cDNA was synthesized by using random primers. qRT-PCR was
carried out by using the ABI 7500 (Applied Biosystems). The cycling
conditions for real-time PCR were: 50 8C for 10 min, followed by 45
cycles of 95 8C for 30 s, and 60 8C for 2 min. Data were analyzed by
using the Sequence Detection v1.2 Analysis Software (Applied
Biosystems).
Statistical analysis. We used a two-tailed t test for two samples for
means with a confidence level (alpha) of 0.05 using Excel Analysis
Tool Pack (Microsoft). Differences in survival and disease were
determined at the FCCC Biostatistics and Bioinformatics Facility
using Log Rank Test with the STATE SE/9.2 software. In all cases,
differences were considered significant when p-values were  0.05.
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